Moe Alsumidaie is Chief Editor of The Clinical Trial Vanguard. Moe holds decades of experience in the clinical trials industry.
Moe also serves as Head of Research at CliniBiz and Chief Data Scientist at Annex Clinical Corporation.
ImmunityBio announced that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has accepted its marketing authorization application for...
Pfizer announced positive Phase 3 TALAPRO-2 trial results for TALZENNA (talazoparib) combined with XTANDI (enzalutamide) in treating metastatic castration-resistant...
UCB’s Bimzelx (bimekizumab), a dual IL-17A/IL-17F inhibitor for psoriatic arthritis (PsA), is demonstrating strong early adoption among rheumatologists just...